News
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...
Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results